Literature DB >> 22323748

Role of DaTSCAN and clinical diagnosis in Parkinson disease.

Raúl de la Fuente-Fernández1.   

Abstract

OBJECTIVE: To assess the role of DaTSCAN in the diagnosis of Parkinson disease (PD).
METHODS: Using the sensitivity and specificity values obtained in the 2 studies that recently led the US Food and Drug Administration to approve the use of DaTSCAN for the diagnosis of PD, calculations were carried out to estimate the accuracy of the clinical diagnosis taking DaTSCAN findings as the standard of truth.
RESULTS: In early PD, a clinical diagnosis of "possible" or "probable" PD has a sensitivity of 98% and a specificity of 67%. The specificity increases to 94% once the clinical diagnosis becomes established. The overall accuracy of the clinical diagnosis is 84% in early PD and 98% at later stages. The clinical diagnostic accuracy is mathematically identical to the diagnostic accuracy of DaTSCAN imaging.
CONCLUSIONS: In the absence of neuropathologic validation, the overall accuracy of a clinical diagnosis of PD is very high and mathematically identical to the accuracy of DaTSCAN imaging, which calls into question the use of radiotracer neuroimaging as a diagnostic tool in clinical practice.

Entities:  

Mesh:

Year:  2012        PMID: 22323748     DOI: 10.1212/WNL.0b013e318248e520

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

Review 3.  The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.

Authors:  Ke-Ru Li; An-Guo Wu; Yong Tang; Xiao-Peng He; Chong-Lin Yu; Jian-Ming Wu; Guang-Qiang Hu; Lu Yu
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

4.  Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning.

Authors:  Yu Zhao; Jianjun Wu; Ping Wu; Matthias Brendel; Jiaying Lu; Jingjie Ge; Chunmeng Tang; Jimin Hong; Qian Xu; Fengtao Liu; Yimin Sun; Zizhao Ju; Huamei Lin; Yihui Guan; Claudio Bassetti; Markus Schwaiger; Sung-Cheng Huang; Axel Rominger; Jian Wang; Chuantao Zuo; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-19       Impact factor: 10.057

5.  Handwriting as an objective tool for Parkinson's disease diagnosis.

Authors:  Sara Rosenblum; Margalit Samuel; Sharon Zlotnik; Ilana Erikh; Ilana Schlesinger
Journal:  J Neurol       Date:  2013-06-16       Impact factor: 4.849

6.  The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Authors:  Nevein Ibrahim; Joanna Kusmirek; Aaron F Struck; John M Floberg; Scott B Perlman; Catherine Gallagher; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

7.  Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).

Authors:  Mike A Nalls; Margaux F Keller; Dena G Hernandez; Lan Chen; David J Stone; Andrew B Singleton
Journal:  Mov Disord       Date:  2015-08-13       Impact factor: 10.338

8.  Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.

Authors:  Elina Jaakkola; Juho Joutsa; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2015-12-16       Impact factor: 3.575

9.  The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson's Disease.

Authors:  Ece Bayram; Nikki Kaplan; Guogen Shan; Jessica Z K Caldwell
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2019-08-14

10.  Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease.

Authors:  Jonathan R Isaacson; Salima Brillman; Nisha Chhabria; Stuart H Isaacson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.